Royalty Report: Drugs, Disease, Gastrointestinal – Collection: 336318

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 12

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 12

Primary Industries

  • Drugs
  • Disease
  • Gastrointestinal
  • Therapeutic
  • Pharmaceuticals
  • Bacterial Infection
  • Drug Discovery
  • Surgical
  • Diagnostic
  • Technical Know How
  • Cancer

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 336318

License Grant
Japanese Licensor hereby grants to Licensee, during the Term, an exclusive, royalty-bearing license, with the right to sublicense, under the Licensor Technology (other than Licensor Improvements) to develop, use, distribute, import and export Compounds and to develop, register, use, distribute, promote, market, offer for sale, sell, have sold, import and export Products, in each case only in the Field and in the Licensed Territory. Licensor further grants Licensee an exclusive license, with the right to sublicense, to use Licensor Technology (other than Licensor Improvements) to the extent necessary to formulate or have Compounds formulated into bulk Product and package bulk Product into finished Product, solely for sale of Products in the Field and in the Licensed Territory. Without limiting the foregoing, under the license granted under this agreement, Licensor hereby grants to Licensee, during the Term, an exclusive right to access, use and reference all clinical data and regulatory filings, correspondence and approvals of Licensor in order to develop, use, distribute, import and export Compounds and to develop, register, use, distribute, promote, market, offer for sale, sell, have sold, import and export Products, in each case only for the Field and for the Licensed Territory.
License Property
Compound shall mean (a) the drug substance which is known as Kremezin (AST-120), which shall be the spherical adsorptive carbon described in DMF Number 16077 as of the Effective Date, (b) any other carbon-based adsorbent product(activated carbon) consisting of more than 90% carbon, Controlled by Licensor or its Affiliates, which is equivalent or alternative to Kremezin (AST-120), as such terms are defined in the FDA’s “Orange Book” or comparable regulatory standards of the EMEA, or (c) any composition covered under Licensor Technology, which is equivalent or alternative to Kremezin (AST-120), as such terms are defined in the FDA’s “Orange Book” or regulatory standards of the EMEA.

Licensor Patents shall mean
U.S. Patent # 6,830,753 – Adsorbent for oral administration
U.S. Patent # 5,686,081 – Divided package of adsorbent for internal use
U.S. Patent # 5,554,370 – Method for the treatment of inflammatory bowel diseases

Field of Use
Field shall mean any human therapeutic indications in the areas of Gastro-Intestinal Disease and Liver Disease.

This pivotal, double-blind, placebo controlled study, FHAST1 (Fistula Healing with AST-120), has been designed to determine the efficacy and safety of oral AST-120 in 240 patients with Crohn's disease suffering from perianal fistulas.  AST-120 is an oral agent known to adsorb bile acids, toxins and mediators of inflammation from the gastrointestinal tract with the potential to address multiple gastrointestinal diseases.

Licensee also recently announced the initiation of Phase 2 trials with AST-120 in Irritable Bowel Syndrome and Hepatic Encephalopathy.
Irritable bowel syndrome (IBS), referred to previously as spastic or nervous colon, and spastic bowel, is a functional gastrointestinal disorder characterized by a group of symptoms accompanied together that include abdominal pain and changes in the consistency of bowel movements.  Irritable bowel syndrome (IBS) is a common disorder that affects the large intestine. Signs and symptoms include cramping, abdominal pain, bloating, gas, and diarrhea or constipation, or both. IBS is a chronic condition that you'll need to manage long term.

Hepatic encephalopathy (HE) is a common neuropsychiatric complication of liver disease.

IPSCIO Record ID: 266736

License Grant
Licensor, a non-profit hospital, grants to Licensee to the extent of the Licensed Territory an exclusive license under the patent rights to make, have made, use, sell and have sold, and import licensed products in the Licensed Field, with the right to sub license.

Licensor grants to the extent of the Licensed Territory a nonexclusive license to use the Licensed Technology as necessary to exploit all rights granted with respect to the patent rights in the Licensed Field, with the right to sublicense.

License Property
Licensor owns US Patent application for Methods of Treating Irritable Bowel Syndrome and Other Disorders Caused by Small Intestinal Bacterial Overgrowth, and, US Patent entitled Methods of Diagnosing or Treating Irritable Bowel Syndrome and Other Disorders Caused by Small Intestinal Bacterial Overgrowth.

Rifaximin means rifaximin, any pharmaceutical equivalents, salts and derivatives thereof.

Field of Use
Rifaximin is an antibiotic used to treat traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy.

IPSCIO Record ID: 233469

License Grant
The Licensor of England grants to Licensee of Bermuda the exclusive right and license under the Patent Rights, the Technical Information and Manufacturing Technology to develop, have developed, make, have made, use, sell and have sold Products within the Territory. Notwithstanding the foregoing, Licensor may authorize a Specific Third Party, its Affiliates and successors to manufacture Balsalazide within the Territory solely for sale and use outside the Territory.
License Property
The patents and technology are related to Balsalazide, or to prodrugs, analogs or isomers thereof or improvements of any of the foregoing, obtained in any country within the Territory.

Balsalazide means 5-[4(2-Carboxyethelcarbamoyl)-phenylazo] – salicylic acid disodium salt dihydrate.

Products means products incorporating Balsalazide, whether or not such products are covered by the Patent Rights, or any other material whose manufacture, use or sale by an unlicensed third party would constitute an infringement of any Valid Claim included within the Patent Rights.

Field of Use
The product is used for gastrointestinal disease.

First marketed product, Colazal, was the first new molecular entity approved in 10 years by the FDA for the treatment of mildly to moderately active ulcerative colitis and the first new oral therapy approved by the FDA for this indication in seven years.  Ulcerative colitis is a chronic form of inflammatory bowel disease characterized by inflammation of the lining of the colon. Symptoms of active ulcerative colitis include rectal bleeding, abdominal pain, increased stool frequency, loss of appetite, fever and weight loss.

IPSCIO Record ID: 314635

License Grant
South Korean Licensor shall, and hereby does, grant to Licensee an exclusive (even as to Licensor and its Affiliates), royalty-bearing right and license, including the right to sublicense in accordance with this Agreement, under the Licensor Intellectual Property and Licensor’s interest in the Joint Intellectual Property, to Develop, Manufacture, use and Commercialize, including filing for, obtaining and maintaining Regulatory Approval for, Products in the Field in the Territory.
License Property
Product means any pharmaceutical preparation containing one or more Compounds either as its only active ingredient(s) or as part of a Combination Product. For the avoidance of doubt, nothing in this Agreement grants to Licensee or Licensor any right or license under any Patent Rights or Know-How Controlled by Licensor or Licensee, respectively, with respect to any Other API.

Compound means YH12852, which has the chemical structure set forth in this agreement, together with all analogs, derivatives, metabolites, stereoisomers, polymorphs, formulations, mixtures or compositions thereof, and any existing or future improved or modified versions of the foregoing developed by or on behalf of Licensee, its Affiliates or Sublicensees.

Compound (S)-N-(1-(2-((4-amino-3-nitrophenyl)amino)-6-propylpyrimidin-4-yl)pyrrolidin-3-yl)acetamide

Licensor Patent Rights means all Patent Rights in the Territory that are Controlled by Licensor or any of its Affiliates as of the Effective Date or thereafter during the Term (other than Joint Patent Rights) that Cover any Compound or Product. The Licensor Patent Rights existing as of the Effective Date are set forth on Schedule 1.57; provided, however, that, if Licensor is acquired by a Third Party, “Licensor Patent Rights” shall exclude any Patent Rights that (a) are Controlled by such Third Party or the Affiliates of such Third Party (other than Licensor and Licensor Pre-Existing Affiliates) and (b) were not Controlled by Licensor or any of the Licensor Pre-Existing Affiliates immediately prior to the closing of such acquisition transaction; provided further that, if, after the closing of such acquisition, any such Licensor Excluded Affiliate has or acquires Control of any Patent Right that Covers the Development, Manufacture or Commercialization of any Compound or Product and that is used to Develop, Manufacture or Commercialize any such Compound or Product, such additional Patent Right that is Controlled by such Licensor Excluded Affiliate shall be included in Licensor Patent Rights.

9,890,138 – Diaminopyrimidine derivatives and processes for the preparation thereof
10,227,330 – Diaminopyrimidine derivatives and processes for the preparation thereof
9,850,227 – Diaminopyrimidine derivatives and processes for the preparation thereof

Licensee is a global pharmaceutical company offering one-stop custom synthesis services of active pharmaceutical products (APIs) and intermediates.

YH12852 is a novel, potent and highly selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist. Other 5-HT receptor agonists with less 5-HT4 selectivity have been shown to successfully treat GI mobility disorders such as chronic constipation, constipation-predominant irritable bowel syndrome, functional dyspepsia and gastroparesis.

Field of Use
YH12852 is a small molecule drug in development for the treatment of functional gastrointestinal (GI) disorders (FGID).

IPSCIO Record ID: 2810

License Grant
Licensor grants an exclusive license to make, have made, use or sell for use in the Field within the United States and its territories (Puerto Rico, Guam), Canada and Mexico.  The Compound and Product pursuant to all Licensor’s Intellectual Property Rights.
License Property
Licensor has discovered a compound internally designated as LY315535 (5,434,174) which may be useful in the treatment of functional gastrointestinal disorders and other indications.

Compound means 2-di-n-propylamino-8-(isoxazol-5-yl)-1,2,3,4-tetrahydronaphthalene and all pharmaceutically acceptable salts and solvates.

Field of Use
Field means products for Gastrointestinal Indications.  
Gastrointestinal Indications means disease states, such as excess gastric acid secretion, inflammatory bowel disease, irritable bowel syndrome, gastroesophagael reflux disease, esophagitis, dyspepsia, proctitis, hemorrhoids, gastrointestinal ulceration, nausea and vomiting and constipation and diarrhea, which are characterized by abnormalities of the Digestive System, regardless of the mechanism involved in such disease states.

IPSCIO Record ID: 263902

License Grant
The Licensor of Germany grants, in respect of the Licensor Patents, the Licensor IP and the Licensor Product Data the sole and exclusive royalty bearing right and license to use the same and to develop, use and Exploit the Product throughout the Territory and a non-exclusive right and license to manufacture and have manufactured the Product in any part of the world for Exploitation in the Territory only.
License Property
The licensed property is a pellet formulation of mesalamine.  

The name of the product is Salofalk® 500 mg, Granu-Stix®.   Salofalk Granu-Stix delivers the therapeutically active antiinflammatory agent mesalamine (5-aminosalicylic acid or 5-ASA) to the distal ileum and colon by means of dual-release granules.

The patents include Pellet formulation for the treatment of the intestinal tract,  and, Pellet-type formulation intended for treating the intestinal tract.

Field of Use
The field of use is for the treatment of acute episodes and the maintenance of remission of ulcerative colitis.
Ulcerative colitis (UC) is a disease that affects your large intestine, or colon. It causes irritation and swelling called inflammation. … UC is a type of inflammatory bowel disease, but it's different from other diseases with similar symptoms, like Crohn's disease or irritable bowel syndrome.

IPSCIO Record ID: 264191

License Grant
The Company executed a license agreement with the University for a worldwide, exclusive license to manufacture, market, sell and sublicense Extracellular Matrix Hydrogel.
License Property
ExtraCellular Matrix Hydrogel (“ECMH”), targets the treatment of multiple gastrointestinal diseases, including Ulcerative Colitis, Crohn’s Disease, and Rectal Mucositis.
Field of Use
This agreement pertains to the drug industry with a field of use limited to human and animal colonic and small intestine therapeutic indications.

ExtraCellular Matrix Hydrogel (ECMH), is a first-in-class, non-pharmacologic, non-surgical treatment option for patients suffering from Ulcerative Colitis.
Ulcerative colitis (UC) is a long-term condition that results in inflammation and ulcers of the colon and rectum. The primary symptoms of active disease are abdominal pain and diarrhea mixed with blood. Weight loss, fever, and anemia may also occur.

IPSCIO Record ID: 367311

License Grant
Canadian Licensor hereby grants to German Licensee an exclusive, royalty-bearing right and license, with the right to grant sublicenses solely as set forth in this agreement, under the Licensor Intellectual Property and Licensor’s rights in the Joint Intellectual Property to the extent necessary or useful to Develop and Commercialize the Compound and Product in the Field in the Territory.

Licensor hereby grants to Licensee a co-exclusive right and license, with the right to grant sublicenses solely as set forth in this agreement, under the Licensor Intellectual Property and Licensor’s rights in the Joint Intellectual Property to the extent necessary or useful to Manufacture the Compound and Product in the Field in the Territory for Development and Commercialization by Licensee in the Territory.

License Property
Compound shall mean the compound known as teduglutide, as further described, and any analogues, fragments, derivatives, receptors and compositions thereof.
USAN – TEDUGLUTIDE

Therapeutic Claim – treatment of intestinal diseases characterized by chemical or surgical damage of the intestinal epithelium such as Short Bowel Syndrome (SBS) or damage to the intestinal epithelium due to disease (glucagon-like peptide-2 (GLP-2) analog)

Licensor Patent Rights shall mean Patent Rights, to the extent that they (a) Cover Licensor Know-How or are directly related to the Manufacture, use, Commercialization or Development of Compound or Product in the Field, and (b) are Controlled by Licensor, but shall not include Joint Patent Rights.

GATTEX is an analog of glucagon-like peptide 2, a naturally occurring hormone that regulates proliferation of the cells lining the small intestine. Licensor is independently investigating GATTEX as a potential treatment for short bowel syndrome, or SBS, and other indications, including Crohn’s disease, chemotherapy-induced enteritis, necrotizing enterocolitis and various other gastrointestinal diseases.

Field of Use
Field shall mean the treatment and diagnosis of all Indications in humans and animals relating to treatment of intestinal diseases characterized by chemical or surgical damage of the intestinal epithelium such as Short Bowel Syndrome (SBS) or damage to the intestinal epithelium due to disease.

IPSCIO Record ID: 367296

License Grant
Licensor (a nonprofit, tertiary, hospital and multispecialty academic health science center) hereby grants to Licensee, and Licensee hereby accepts from Licensor, the exclusive license, with the right to grant sublicenses, under and to the Patent Rights and Technical Information during the term of this Agreement to conduct research in the Field of Use and to make, have made, use, develop, import, have imported, export, have exported, offer for sale, or have offered for sale, sell and/or have sold Licensed Products and Licensed Technology Products in the Field of Use in the Territory. The foregoing grant of exclusivity is made expressly subject to the following

(a) All applicable laws and regulations, including, without limitation, the requirements of federal law as pertain to the manufacture of products within the United States;

(b) All applicable rules of the Funding Agencies which have provided funding to Licensor or to any of its employees (including any of the Inventors) for the development of the Patent Rights and Technical Information; and

(c) The following non-exclusive rights to the Patent Rights and Technical Information, which are retained by Licensor within the Field of Use
(i)  the right to submit for publication the scientific findings from research conducted by or through Licensor or its investigators (including the Inventors) related to the Patent Rights and the Technical Information; and
(ii)  the right (A) to use any tangible or intangible information contained in the Patent Rights or the Technical Information or any Improvements (so long as Licensor shall treat such information as Confidential Information and maintain its confidentiality in accordance with Section 10 hereof), for Licensor’s internal non-commercial scientific, research, internal teaching, non-profit clinical research and other educationally-related and non-commercial (except for charges to its own patients) clinical purposes, where clinical use does not involve a third party funding grant to commercialize such information, and (B) to obtain research funding for further study and development thereof from governmental and other nonprofit organizations (including grant applications).

(d) Notwithstanding any other provision hereof to the contrary, all rights to the Patent Rights, Technical Information and Improvements outside of the Field of Use are retained by Licensor. Furthermore, this Agreement confers no license or rights by implication, estoppel, or otherwise under any patent applications or patents of Licensor other than Patent Rights regardless of whether such patents are dominant or subordinate to Patent Rights.

License Property
Patent Rights
6,861,053 – Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth

6,805,852 – Methods of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth

7,056,686 – Method of diagnosing fibromyalgia caused by small intestinal bacterial overgrowth

Field of Use
Licensed Products relate to new treatment approaches to target non-bacterial intestinal microorganism life forms known as archaea that are associated with intestinal methane production and chronic diseases such as irritable bowel syndrome (IBS), obesity and type 2 diabetes.

Archaea is a group of primitive prokaryotes that based on their distinct characteristics form a separate domain from bacteria and eukaryotes. Bacteria are single-celled primitive organisms that form a domain of organisms diverse in shape, size, structure, and even habitats.

IPSCIO Record ID: 253982

License Grant
Licensor grants an exclusive license, under the Licensor Technology to develop, use, sell, offer for sale, import and/or export Licensed Products in the Territory and in the Field, and make and have made Licensed Products in the Territory for such development, use, sale, offering for sale, importation and/or exportation.

Licensor grants to Licensee, a perpetual, non-exclusive license under the Licensor Technology for Licensees research purposes only.

License Property
Licensor owns or possesses certain patent rights and know-how with respect to motilin agonist compounds.

GI Indication means diseases, disorders or impairments of the gastrointestinal tract, including the esophagus, stomach, pancreas, small and large intestines, colon, and gall bladder.

GI Product means a Licensed Product that has been Approved in a GI Indication.

The compound is 9O-(N-methylamidomethyl)-Ndesmethyl-N-isopropyl-(9S)-9-dihydroerythromycin A.

The patents are for Motilide Compounds, Method for Evaluating Therapeutic Efficacy,  ll-Deoxy-6,9-ether Erythromycin Compounds,  N-Desmethyl-N-substituted-11-deoxyerythromycin Compounds, and,  9-Desoxoerythromycin Compounds as Prokinetic Agents.

Motilin, a hormone that is secreted by the small intestine, stimulates gastrointestinal motility (movement). Erythromycin, a polyketide best known for its antibiotic activity, is an agonist of the motilin receptor that enhances esophageal motility in GERD patients and accelerates gastric emptying in patients with diabetic gastroparesis.

Field of Use
The agreement includes Licensor's clinical candidate, KOS-2187 and related compounds. KOS-2187 has demonstrated improved gastric emptying in preclinical studies and may have therapeutic benefit in gastrointestinal diseases such as gastro- esophageal reflux disease (GERD), or diabetic gastroparesis (delayed gastric emptying).

Licensee believes that the mechanism of action of KOS-2187 and its demonstrated activity as a prokinetic agent are significant indications of its potential as a new approach for the treatment of gastrointestinal diseases.

IPSCIO Record ID: 57817

License Grant
On May 2, 2010, the Licensee received a worldwide, exclusive and perpetual license to use patents and know how relating to BEKINDAâ„¢ from the previous Licensor, a U.S. company, who is now out of business.  On March 7, 2014, the Company entered into a licensing agreement with a U.S. University to secure certain patent rights related to the drug candidate. The Company therefore terminated the agreement with the U.S. company and licensed the patents directly from the U.S. university, the original owner of the patents. Under the agreement, the Company agreed to pay the U.S. university certain future payments.
License Property
BEKINDAâ„¢ is a once-daily controlled release oral formulation of ondansetron, a leading member of the family of 5HT-3 serotonin receptor inhibitors for the treatment of gastroenteritis and gastritis.

Gastroenteritis, also known as infectious diarrhea, is inflammation of the gastrointestinal tract—the stomach and small intestine.
Gastritis is inflammation of the lining of the stomach.

Field of Use
The biopharmaceutical company is focused on the development and acquisition of late clinical-stage, proprietary, orally-administered drugs for the treatment of inflammatory and gastrointestinal diseases and cancer.

1)
Gastroenteritis and gastritis – 24 mg strength

2)
Irritable Bowel Syndrome with Diarrhea (IBS-D) – 12 mg strength

3)
Prevention of chemotherapy and radiotherapy induced nausea and vomiting (oncology support) – 24 mg strength

IPSCIO Record ID: 266852

License Grant
The German Licensor grants an exclusive, except with regard to Licensor, world-wide right and license under the Licensor Patents and Licensor Know-How and Licensors rights in the Joint Patents, Joint Know-How and Joint Research Technology, to conduct the Research.

Licensor grants the exclusive right to use and to disclose to Third Parties all regulatory and clinical documentation and data developed by or on behalf of Licensor in the Territory in connection with this Agreement and required to be disclosed to Licensee under this Agreement, as reasonably necessary or desirable in connection with the development and commercialization of pharmaceutical products in the Field in the Rest of World or outside the Field throughout the world.

Licensor agrees to negotiate in good faith with Licensee concerning the terms of a license under the Licensor Patents and the Licensor Know-How covering the composition of matter or the use of the Terminated Compounds, to permit Licensee to research, develop, make, have made, import, use, sell and offer for sale the Terminated Compounds outside the Field throughout the world.

Licensor grants an exclusive, including with regard to Licensor, right and license in the Rest of World under the Licensor Patents and the Licensor Know-How and under Licensors rights in the Joint Patents, Joint KnowHow and Joint Research Technology, to research and develop, and to make, have made, import, use, sell and offer for sale pharmaceutical products, including Licensed Products, in the Field.

License Property
Licensor is engaged in the research, development and marketing of products for the treatment of, among other things, ulcerative colitis.

Licensed Product means any product, including any formulation thereof, containing or comprising a Development Compound.  Development Compound means any Collaboration Compound that has
been selected as such hereunder, or any salt, solvate, prodrug form, inclusion complex, metabolite or other formulation thereof.

The technology means proprietary know-how of Licensee and its Affiliates concerning structure activity, relationships of Nicotinic Compounds and nicotinic receptors, pharmacophore mapping of nicotinic receptors and computational and quantum mechanical methods for use in the design, synthesis and evaluation of pharmacologically active agents, including but not limited to Nicotinic Compounds.

Compounds include -240312 Enema-Induction, and, -240312 Oral-Induction/Maintenance.

Field of Use
Field means the treatment or prevention in humans of one or more Indications.   Indication means ulcerative colitis; and other gastrointestinal and liver diseases.

Licensee possesses proprietary technology and know-how related to the discovery, identification and synthesis of nicotinic agonists and has identified and applied for patents on certain nicotinic agonist compounds.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.